← Eichor
Study identifier: NCT03588286 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)

Condition: Sudden Cardiac Death  ·  Sponsor: Western Sydney Local Health District

PhaseNA
Planned participants1058
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

The PROTECT-ICD trial is a physician-led, multi-centre randomised controlled trial targeting prevention of sudden cardiac death in patients who have poor cardiac function following a myocardial infarct (MI). The trial aims to assess the role of electrophysiology study (EPS) in guiding implantable cardioverter-defibrillator (ICD) implantation, in patients early following MI (first 40 days). The secondary aim is to assess the utility of cardiac MRI (CMR) in analysing cardiac function and viability as well as predicting inducible and spontaneous ventricular tachyarrhythmia when performed early post MI. Following a MI patients are at high risk of sudden cardiac death (SCD). The risk is highest in the first 40 days; however, current guidelines exclude patients from receiving an ICD during this time. This limitation is based largely on a single study, The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT), which failed to demonstrate a benefit of early ICD implantation. However, this study was underpowered and used non-invasive tests to identify patients at high risk. EPS identifies patients with the substrate for re-entrant tachyarrhythmia, and has been found in multiple studies to predict patients at risk of SCD. Contrast-enhanced CMR is a non-invasive test without radiation exposure which can be used to assess left ventricular function. In addition, it provides information on myocardial viability, scar size and tissue heterogeneity. It has an emerging role as a predic…

This description comes directly from the study's public registry record.

Talk to the study team

Pramesh Kovoor  ·  +61 2 8890 6030  ·  pramesh.kovoor@sydney.edu.au

Anjalee T Amarasekera  ·  +61 2 8890 4719  ·  Anjalee.Amarasekera@health.nsw.gov.au

Always discuss trial participation with your own doctor first.

Locations (52)

Beth Israel Deaconess Medical CenterBoston, Massachusetts, United StatesNot Yet Recruiting
Canberra HospitalGarran, Australian Capital Territory, AustraliaRecruiting
Nepean HospitalKingswood, New South Wales, AustraliaRecruiting
John Hunter HospitalNew Lambton Heights, New South Wales, AustraliaRecruiting
Prince of Wales HospitalRandwick, New South Wales, AustraliaRecruiting
Royal North Shore HospitalSaint Leonards, New South Wales, AustraliaRecruiting
Westmead HospitalWestmead, New South Wales, AustraliaRecruiting
Wollongong HospitalWollongong, New South Wales, AustraliaRecruiting
Sunshine Coast University HospitalBirtinya, Queensland, AustraliaRecruiting
Carins HospitalCairns, Queensland, AustraliaRecruiting
The Prince Charles HospitalChermside, Queensland, AustraliaRecruiting
The Townsville HospitalDouglas, Queensland, AustraliaRecruiting

+ 40 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03588286